| アブストラクト | INTRODUCTION: This analysis was conducted to assess the incidence of adverse clinical outcomes, healthcare resource use (HCRU), and the costs associated with systemic corticosteroid (SCS) use in adults with systemic lupus erythematosus (SLE) in the UK. METHODS: We identified incident SLE cases using the Clinical Practice Research Datalink GOLD, Hospital Episode Statistics-linked healthcare, and Office for National Statistics mortality databases from January 1, 2005, to June 30, 2019. Adverse clinical outcomes, HCRU, and costs were captured for patients with and without prescribed SCS. RESULTS: Of 715 patients, 301 (42%) had initiated SCS use (mean [standard deviation (SD)] 3.2 [6.0] mg/day) and 414 (58%) had no recorded SCS use post-SLE diagnosis. Cumulative incidence of any adverse clinical outcome over 10-year follow-up was 50% (SCS group) and 22% (non-SCS group), with osteoporosis diagnosis/fracture most frequently reported. SCS exposure in the past 90 days was associated with an adjusted hazard ratio of 2.41 (95% confidence interval 1.77-3.26) for any adverse clinical outcome, with increased hazard for osteoporosis diagnosis/fracture (5.26, 3.61-7.65) and myocardial infarction (4.52, 1.16-17.71). Compared to low-dose SCS (< 7.5 mg/day), patients on high-dose SCS (>/= 7.5 mg/day) had increased hazard for myocardial infarction (14.93, 2.71-82.31), heart failure (9.32, 2.45-35.43), osteoporosis diagnosis/fracture (5.14, 2.82-9.37), and type 2 diabetes (4.02 1.13-14.27). Each additional year of SCS use was associated with increased hazard for any adverse clinical outcome (1.15, 1.05-1.27). HCRU and costs were greater for SCS users than non-SCS users. CONCLUSIONS: Among patients with SLE, there is a higher burden of adverse clinical outcomes and greater HCRU in SCS versus non-SCS users. |
|---|
| ジャーナル名 | Rheumatology and therapy |
|---|
| Pubmed追加日 | 2023/7/4 |
|---|
| 投稿者 | Stirnadel-Farrant, Heide A; Golam, Sarowar M; Naisbett-Groet, Barbara; Gibson, Danny; Langham, Julia; Langham, Sue; Samnaliev, Mihail |
|---|
| 組織名 | BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.;heide.stirnadel-farrant@astrazeneca.com.;Oncology Business Unit, AstraZeneca, AstraZeneca Academy House, 136 Hills Road,;Cambridge, CB2 8PA, UK. heide.stirnadel-farrant@astrazeneca.com.;BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.;Health Economics, AstraZeneca, Cambridge, UK.;Epidemiology Group, Maverex Limited, Newcastle-Upon-Tyne, UK.;Health Economics Group, Maverex Limited, Newcastle-Upon-Tyne, UK.;Statistical Group, Maverex Limited, Newcastle-Upon-Tyne, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37400682/ |
|---|
